South China Morning Post
A Hong Kong co-led global study has found that a targeted therapy can keep more than half of advanced lung cancer patients alive without disease progression for at least seven years, marking a step towards turning the deadly illness into a chronic condition. Researchers from the Chinese University of Hong Kong on Wednesday released the findings of their study, which looked into the efficacy of the third-generation targeted therapy lorlatinib on patients with advanced lung cancer. The study...
Go to News Site
The Straits Times World
大纪元新闻网
大纪元新闻网
CNA Sport
The Straits Times World
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post
South China Morning Post